Cancer Cell Workflow (cc-workflow)
Overview
This is the router. It does not replace any specialized skill — it tells you which cc- skill to use at your current stage* of a Cancer Cell (Cell Press) molecular / translational oncology manuscript.
Default assumption: unless the user says otherwise, treat the target as Cancer Cell, where the bar is a clear molecular mechanism validated across orthogonal systems (cells + in vivo + ideally human data), reported with STAR Methods rigor, framed for translational relevance without overclaiming.
When to trigger
- The user asks "what should I do next?"
- A draft arrives and you must diagnose the current bottleneck
- Work is thrashing between experiments, figures, and writing
- A decision letter / reviewer reports arrive and you must switch into revision mode
Routing table
| Current symptom |
Next skill |
| Unsure whether the story is a Cancer Cell paper at all |
cc-scope-fit |
| Mechanism rests on one system (cells only / no in vivo / no human data) |
cc-study-design |
| Controls, replicates, randomization, or blinding are unclear |
cc-study-design |
| No Key Resources Table; cell lines unauthenticated; antibodies unvalidated |
cc-reporting-standards |
n undefined, pseudo-replication risk, wrong test, error bars unlabeled |
cc-statistics |
| Representative images with no quantification; multi-panel figure messy |
cc-figures-tables |
| Need Summary / Highlights / eTOC blurb / graphical abstract |
cc-structured-abstract |
| Missing IACUC/IRB approval, consent, biosafety, or data-availability statement |
cc-ethics-registration |
| Prose overclaims; Results read like a lab notebook; weak Discussion |
cc-writing-style |
| Need a cover letter framing fit and significance |
cc-cover-letter |
| About to submit and need a final preflight |
cc-submission |
| Reviewer reports arrived; need a point-by-point response |
cc-peer-review-revision |
Default order
cc-scope-fit — confirm mechanism + translational relevance before investing more
cc-study-design — design / audit orthogonal validation, controls, replicates, in vivo rigor
cc-reporting-standards — STAR Methods, Key Resources Table, authentication, RRIDs
cc-statistics — define n, pick tests, correct for multiplicity, label error bars
cc-figures-tables — multi-panel mechanistic figures with quantification + image integrity
cc-structured-abstract — Summary, Highlights, eTOC blurb, graphical abstract
cc-ethics-registration — approvals, consent, biosafety, data-deposition statements
cc-writing-style — Cell Press prose and claim calibration (polish stage)
cc-cover-letter — significance / fit / suggested reviewers
cc-submission — pre-submission preflight
cc-peer-review-revision — after reviewer reports
cc-writing-style and cc-structured-abstract are late-stage polish — do not finalize them while the mechanism or in vivo validation is still missing.
Decision shortcuts
- "It's only in cell lines" →
cc-study-design (add in vivo / human validation)
- "Reviewers will ask if the cell line is authenticated" →
cc-reporting-standards
- "I used n=3 wells from one experiment" →
cc-statistics (pseudo-replication)
- "I have a beautiful blot but no densitometry" →
cc-figures-tables
- "My title promises a therapy but I have no in vivo efficacy" →
cc-scope-fit then cc-writing-style
- "No GEO accession yet" →
cc-ethics-registration / cc-submission
- "Three reviewers, consultative cross-review" →
cc-peer-review-revision
Differences vs. JAMA-style clinical packs
If the work is a clinical trial or epidemiological cohort with patient-level outcomes as the core unit, a clinical-trial pack (CONSORT / STROBE / registration) fits better. Cancer Cell's unit is a mechanism validated across systems, not a trial endpoint.
Worked routing example
"We have RNA-seq showing MARK7 correlates with CAF activation in a patient cohort, plus a knockdown
migration phenotype in one PDAC line. We want to submit to Cancer Cell."
Route it:
cc-scope-fit — a correlation + single-line phenotype is off-fit on both pillars; the mechanism
is not established and there is no in vivo/orthogonal validation. Gate here first.
cc-study-design — plan the missing spine: in vivo perturbation in an immunocompetent model, a
second cell system, and a mechanistic intermediate linking MARK7 to the phenotype.
- Only once that evidence exists do
cc-reporting-standards → cc-statistics → cc-figures-tables
apply; drafting front matter (cc-structured-abstract, cc-writing-style) before then is premature.
The router's job is to stop a promising-but-thin story from being polished into a confident desk reject.
Stage diagnosis cues
| What the user says |
Likely stage |
Route |
| "Is this even a Cancer Cell paper?" |
Pre-scope |
cc-scope-fit |
| "Reviewers will ask about in vivo" |
Design gap |
cc-study-design |
| "My Methods feel thin" |
Reporting |
cc-reporting-standards |
| "Is n=3 wells enough?" |
Statistics |
cc-statistics |
| "The blot has no quantification" |
Display |
cc-figures-tables |
| "The Summary buries the finding" |
Front matter |
cc-structured-abstract |
| "I have no GEO accession" |
Ethics/deposition |
cc-ethics-registration |
| "Final check before upload" |
Preflight |
cc-submission |
| "Three reviewers came back" |
Revision |
cc-peer-review-revision |
Evidence-spine manifest
Cancer Cell's unit is a mechanism validated across orthogonal systems. Track the spine as a
manifest and route on the first MISSING: front-matter polish is premature until cells +
in vivo + (ideally) human evidence converge on one mechanism.
evidence_spine:
mechanism: OK | UNCLEAR # molecular intermediate linking cause -> phenotype
cell_system_1: OK | MISSING
cell_system_2: OK | MISSING # orthogonal line / method, not a technical replicate
in_vivo: OK | MISSING # perturbation in an immunocompetent model
human_data: OK | MISSING # patient cohort / clinical specimens
rigor:
key_resources_table: yes | no # cc-reporting-standards
cell_line_authenticated: yes | no
n_defined_no_pseudorep: yes | no # cc-statistics
image_quantification: yes | no # cc-figures-tables
deposition:
geo_or_pride_accession: yes | no # cc-ethics-registration
route_rule: "first MISSING/UNCLEAR above -> its listed skill; do not draft Summary/Highlights until the spine is OK"
Anti-patterns
- Do not skip
cc-scope-fit — editors triage on mechanism + translational fit first
- Do not let
cc-figures-tables polish panels before cc-statistics has fixed n and tests
- Do not let
cc-peer-review-revision draft a response before the revised experiments / text exist
- Do not route to front-matter polish while the in vivo or human-validation spine is still missing
- Do not treat a presubmission inquiry as a substitute for the scope gate — run
cc-scope-fit regardless
Source: brycewang-stanford/Awesome-Journal-Skills → Cancer-Cell-Skills/skills/cc-workflow/SKILL.md
1---2name: cc-workflow3description: Use when deciding which cc-* sub-skill to invoke next, or when sequencing a Cancer Cell (Cell Press) manuscript from scope check through peer-review revision. Routes — it does not replace — the specialized skills.4---5
6
7# Cancer Cell Workflow (cc-workflow)
8
9## Overview
10
11This is the router. It does not replace any specialized skill — it tells you **which cc-* skill to use at your current stage** of a Cancer Cell (Cell Press) molecular / translational oncology manuscript.
12
13Default assumption: unless the user says otherwise, treat the target as **Cancer Cell**, where the bar is a clear molecular mechanism validated across orthogonal systems (cells + in vivo + ideally human data), reported with STAR Methods rigor, framed for translational relevance without overclaiming.
14
15## When to trigger
16
17- The user asks "what should I do next?"
18- A draft arrives and you must diagnose the current bottleneck
19- Work is thrashing between experiments, figures, and writing
20- A decision letter / reviewer reports arrive and you must switch into revision mode
21
22## Routing table
23
24| Current symptom | Next skill |
25|------------------------------------------------------------------------|-----------------------------|
26| Unsure whether the story is a Cancer Cell paper at all | `cc-scope-fit` |
27| Mechanism rests on one system (cells only / no in vivo / no human data) | `cc-study-design` |
28| Controls, replicates, randomization, or blinding are unclear | `cc-study-design` |
29| No Key Resources Table; cell lines unauthenticated; antibodies unvalidated | `cc-reporting-standards` |
30| `n` undefined, pseudo-replication risk, wrong test, error bars unlabeled | `cc-statistics` |
31| Representative images with no quantification; multi-panel figure messy | `cc-figures-tables` |
32| Need Summary / Highlights / eTOC blurb / graphical abstract | `cc-structured-abstract` |
33| Missing IACUC/IRB approval, consent, biosafety, or data-availability statement | `cc-ethics-registration` |
34| Prose overclaims; Results read like a lab notebook; weak Discussion | `cc-writing-style` |
35| Need a cover letter framing fit and significance | `cc-cover-letter` |
36| About to submit and need a final preflight | `cc-submission` |
37| Reviewer reports arrived; need a point-by-point response | `cc-peer-review-revision` |
38
39## Default order
40
411. `cc-scope-fit` — confirm mechanism + translational relevance before investing more
422. `cc-study-design` — design / audit orthogonal validation, controls, replicates, in vivo rigor
433. `cc-reporting-standards` — STAR Methods, Key Resources Table, authentication, RRIDs
444. `cc-statistics` — define `n`, pick tests, correct for multiplicity, label error bars
455. `cc-figures-tables` — multi-panel mechanistic figures with quantification + image integrity
466. `cc-structured-abstract` — Summary, Highlights, eTOC blurb, graphical abstract
477. `cc-ethics-registration` — approvals, consent, biosafety, data-deposition statements
488. `cc-writing-style` — Cell Press prose and claim calibration (polish stage)
499. `cc-cover-letter` — significance / fit / suggested reviewers
5010. `cc-submission` — pre-submission preflight
5111. `cc-peer-review-revision` — after reviewer reports
52
53> `cc-writing-style` and `cc-structured-abstract` are **late-stage polish** — do not finalize them while the mechanism or in vivo validation is still missing.
54
55## Decision shortcuts
56
57- "It's only in cell lines" → `cc-study-design` (add in vivo / human validation)
58- "Reviewers will ask if the cell line is authenticated" → `cc-reporting-standards`
59- "I used n=3 wells from one experiment" → `cc-statistics` (pseudo-replication)
60- "I have a beautiful blot but no densitometry" → `cc-figures-tables`
61- "My title promises a therapy but I have no in vivo efficacy" → `cc-scope-fit` then `cc-writing-style`
62- "No GEO accession yet" → `cc-ethics-registration` / `cc-submission`
63- "Three reviewers, consultative cross-review" → `cc-peer-review-revision`
64
65## Differences vs. JAMA-style clinical packs
66
67If the work is a clinical trial or epidemiological cohort with patient-level outcomes as the core unit, a clinical-trial pack (CONSORT / STROBE / registration) fits better. Cancer Cell's unit is a **mechanism validated across systems**, not a trial endpoint.
68
69## Worked routing example
70
71> "We have RNA-seq showing MARK7 correlates with CAF activation in a patient cohort, plus a knockdown
72> migration phenotype in one PDAC line. We want to submit to Cancer Cell."
73
74Route it:
75
761. `cc-scope-fit` — a correlation + single-line phenotype is **off-fit** on both pillars; the mechanism
77 is not established and there is no in vivo/orthogonal validation. Gate here first.
782. `cc-study-design` — plan the missing spine: in vivo perturbation in an immunocompetent model, a
79 second cell system, and a mechanistic intermediate linking MARK7 to the phenotype.
803. Only once that evidence exists do `cc-reporting-standards` → `cc-statistics` → `cc-figures-tables`
81 apply; drafting front matter (`cc-structured-abstract`, `cc-writing-style`) before then is premature.
82
83The router's job is to stop a promising-but-thin story from being polished into a confident desk reject.
84
85## Stage diagnosis cues
86
87| What the user says | Likely stage | Route |
88|--------------------|--------------|-------|
89| "Is this even a Cancer Cell paper?" | Pre-scope | `cc-scope-fit` |
90| "Reviewers will ask about in vivo" | Design gap | `cc-study-design` |
91| "My Methods feel thin" | Reporting | `cc-reporting-standards` |
92| "Is n=3 wells enough?" | Statistics | `cc-statistics` |
93| "The blot has no quantification" | Display | `cc-figures-tables` |
94| "The Summary buries the finding" | Front matter | `cc-structured-abstract` |
95| "I have no GEO accession" | Ethics/deposition | `cc-ethics-registration` |
96| "Final check before upload" | Preflight | `cc-submission` |
97| "Three reviewers came back" | Revision | `cc-peer-review-revision` |
98
99## Evidence-spine manifest
100
101Cancer Cell's unit is a mechanism validated across orthogonal systems. Track the spine as a
102manifest and route on the first `MISSING`: front-matter polish is premature until cells +
103in vivo + (ideally) human evidence converge on one mechanism.
104
105```yaml
106evidence_spine:
107 mechanism: OK | UNCLEAR # molecular intermediate linking cause -> phenotype
108 cell_system_1: OK | MISSING
109 cell_system_2: OK | MISSING # orthogonal line / method, not a technical replicate
110 in_vivo: OK | MISSING # perturbation in an immunocompetent model
111 human_data: OK | MISSING # patient cohort / clinical specimens
112 rigor:
113 key_resources_table: yes | no # cc-reporting-standards
114 cell_line_authenticated: yes | no
115 n_defined_no_pseudorep: yes | no # cc-statistics
116 image_quantification: yes | no # cc-figures-tables
117 deposition:
118 geo_or_pride_accession: yes | no # cc-ethics-registration
119route_rule: "first MISSING/UNCLEAR above -> its listed skill; do not draft Summary/Highlights until the spine is OK"
120```
121
122## Anti-patterns
123
124- **Do not** skip `cc-scope-fit` — editors triage on mechanism + translational fit first
125- **Do not** let `cc-figures-tables` polish panels before `cc-statistics` has fixed `n` and tests
126- **Do not** let `cc-peer-review-revision` draft a response before the revised experiments / text exist
127- **Do not** route to front-matter polish while the in vivo or human-validation spine is still missing
128- **Do not** treat a presubmission inquiry as a substitute for the scope gate — run `cc-scope-fit` regardless
129
130---
131
132**Source:** [`brycewang-stanford/Awesome-Journal-Skills`](https://github.com/brycewang-stanford/Awesome-Journal-Skills) → `Cancer-Cell-Skills/skills/cc-workflow/SKILL.md`